Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers

T. E. Keane; G. Rosner; J. T. Donaldson; D. L. Norwood; S. H. Poulton; P. J. Walther

doi:10.1016/S0022-5347(17)39647-7

Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers

T. E. Keane, G. Rosner, J. T. Donaldson, D. L. Norwood, S. H. Poulton, P. J. Walther

Research output: Contribution to journal › Article › peer-review

Abstract

The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

Original language	English (US)
Pages (from-to)	1004-1009
Number of pages	6
Journal	Journal of Urology
Volume	144
Issue number	4
DOIs	https://doi.org/10.1016/S0022-5347(17)39647-7
State	Published - Jan 1 1990
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/S0022-5347(17)39647-7

Fingerprint Dive into the research topics of 'Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers'. Together they form a unique fingerprint.

Cite this

@article{3bd6d660cc904993a107bdf19e49e26c,

title = "Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers",

abstract = "The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.",

author = "Keane, {T. E.} and G. Rosner and Donaldson, {J. T.} and Norwood, {D. L.} and Poulton, {S. H.} and Walther, {P. J.}",

year = "1990",

month = jan,

day = "1",

doi = "10.1016/S0022-5347(17)39647-7",

language = "English (US)",

volume = "144",

pages = "1004--1009",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Dipyramidole-cisplatin potentiation

T2 - Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers

AU - Keane, T. E.

AU - Rosner, G.

AU - Donaldson, J. T.

AU - Norwood, D. L.

AU - Poulton, S. H.

AU - Walther, P. J.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

AB - The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

UR - http://www.scopus.com/inward/record.url?scp=0025194067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025194067&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(17)39647-7

DO - 10.1016/S0022-5347(17)39647-7

M3 - Article

C2 - 2398547

AN - SCOPUS:0025194067

VL - 144

SP - 1004

EP - 1009

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -